Gene · 51135
Papers3,419
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
701 to 720 of 3,419
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Hepatitis C Virus Infection and Intrinsic Disorder in the Signaling Pathways Induced by Toll-Like Receptors. | Biology (Basel) | 2022 | 36101469 | PubTator, text mining | PubMed |
| Research progress on the mechanism by which skin macrophage dysfunction mediates chronic inflammatory injury in diabetic skin. | Front Endocrinol (Lausanne) | 2022 | 36093074 | PubTator, text mining | PubMed |
| Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper. | Mol Ther Methods Clin Dev | 2022 | 36092368 | PubTator, text mining | PubMed |
| Immunomodulatory effects of new phytotherapy on human macrophages and TLR4- and TLR7/8-mediated viral-like inflammation in mice. | Front Med (Lausanne) | 2022 | 36091684 | PubTator, text mining | PubMed |
| Age-related decline in the resistance of mice to bacterial infection and in LPS/TLR4 pathway-dependent neutrophil responses. | Front Immunol | 2022 | 36090969 | PubTator, text mining | PubMed |
| Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19. | Sci Immunol | 2022 | 36083891 | PubTator, text mining | PubMed |
| Drosophila as a Model for Human Viral Neuroinfections. | Cells | 2022 | 36078091 | PubTator, text mining | PubMed |
| Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure. | Cancers (Basel) | 2022 | 36077850 | PubTator, text mining | PubMed |
| A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges. | Cancers (Basel) | 2022 | 36077703 | PubTator, text mining | PubMed |
| Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. | Biomed Pharmacother | 2022 | 36076574 | PubTator, text mining | PubMed |
| Adult-onset Still's disease: A disease at the crossroad of innate immunity and autoimmunity. | Front Med (Lausanne) | 2022 | 36072947 | PubTator, text mining | PubMed |
| Identification of diagnostic biomarkers and therapeutic targets in peripheral immune landscape from coronary artery disease. | J Transl Med | 2022 | 36064568 | PubTator, text mining | PubMed |
| The overexpression of GPX8 is correlated with poor prognosis in GBM patients. | Front Genet | 2022 | 36061208 | PubTator, text mining | PubMed |
| Stellera chamaejasme L. extracts in the treatment of glioblastoma cell lines: Biological verification based on a network pharmacology approach. | Front Oncol | 2022 | 36059675 | PubTator, text mining | PubMed |
| Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease. | J Hematol Oncol | 2022 | 36045390 | PubTator, text mining | PubMed |
| Binding Energy Partition of Promising IRAK-4 Inhibitor (Zimlovisertib) for the Treatment of COVID-19 Pneumonia. | Chemphyschem | 2022 | 36044560 | PubTator, text mining | PubMed |
| Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. | Elife | 2022 | 36040792 | PubTator, text mining | PubMed |
| Nuclear fascin regulates cancer cell survival. | Elife | 2022 | 36039640 | PubTator, text mining | PubMed |
| Changes in plasma IRAK-M in patients with prediabetes and its relationship with related metabolic indexes: a cross-sectional study. | J Int Med Res | 2022 | 36039603 | PubTator, text mining | PubMed |
| Building Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview. | Curr Pediatr Rep | 2022 | 36034212 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51135/papers?page=36